Analysis of the Expression and Prognosis for Leukocyte Immunoglobulin-Like Receptor Subfamily B in Human Liver Cancer

Abstract Background: Leukocyte immunoglobulin-like receptor subfamily B (LILRB), including 5 subtypes, is a group of inhibitory receptors in immune system. The LILRB family is known to be involved in the tumor progression of various cancer types, especially liver cancer. However, the expression patterns and prognostic values of LILRB family members in liver cancer tissues remain unclear.Methods: We used the Oncomine database, GEPIA database, Kaplan–Meier Plotter, Timer, TISIDB and cBioPortal to assess the expression and prognostic value of the LILRB family in liver cancer patients. We also verified the expression of the LILRB family in tumor tissues and tumor-free liver tissues at the protein level by using immunohistochemistry. The STRING website was used to explore the interaction between the LILRB family and their related genes. The DAVID database was used to perform the GO and KEGG analyses. Flow cytometry was used to assess the infiltrated NK cells in liver cancer tissues.Results: Our study revealed that the mRNA expression of LILRB1, LILRB2, LILRB3 and LILRB5 was downregulated, while compared with normal tissues, the mRNA expression of LILRB4 was upregulated in liver cancer tissues. Survival analysis revealed that LILRB2 and LILRB5 mRNA expression levels were significantly associated with OS and DSS and that the mRNA expression of all LILRB family members was significantly correlated with RFS and PFS. Next, we further found that the mRNA expression of all LILRB family members was significantly associated with the infiltration of B cells, CD8+ T cells, CD4+ T cells, macrophages, and neutrophil dendritic cells in liver cancer. Finally, GO and KEGG analyses found that the LILRB family and its related genes were involved in antigen processing and presentation and natural killer cell-mediated cytotoxicity pathways.Conclusions: Our study suggested that LILRB family expression was associated with the prognosis of liver cancer patients and infiltrated immune cells. The LILRB family might be involved in antigen processing and presentation and natural killer cell-mediated cytotoxicity pathways.

Download Full-text

Comparing of pan-cancer tumor immune microenvironment.

Journal of Clinical Oncology ◽

10.1200/jco.2021.39.15_suppl.e15100 ◽

2021 ◽

Vol 39 (15_suppl) ◽

pp. e15100-e15100

Author(s):

Jiaan Ye ◽

Longgang Cui ◽

Xiaochen Zhao ◽

Guanghui Lan

Keyword(s):

Colorectal Cancer ◽

T Cells ◽

Natural Killer Cell ◽

Natural Killer ◽

Cancer Patients ◽

Killer Cell ◽

Immune Microenvironment ◽

Hepatobiliary Cancer ◽

Tumor Immune Microenvironment ◽

Pan Cancer

e15100 Background: Cancer treatment has entered the era of immune checkpoint inhibitors (ICI), but different tumors have different responses to ICI drugs. For example, non-small cell lung cancer and melanoma have higher response rates to ICIs than colorectal cancer and liver cancer patients. Previous studies have shown that tumor immune microenvironment have a great impact on the efficacy of ICI. Methods: This study retrospectively included pan-cancer patient specimens, using multiple fluorescent labeling immunohistochemistry to explore the differences in the immune microenvironment of different tumors. Shapiro-Wilk was used for normality test, and ANOVA or Kruskal Wallis test was used according to the results. Two-sided P < 0.05 was considered a significant difference. Results: The study included 308 patients, including 119 (38.6%) NSCLC patients, 72 (23.4%) Colorectal cancer patients, 51 (16.6%) Hepatobiliary cancer patients and 66 (21.4%) Others types of cancer patients. Among them, there was 192 (62.3%) Male, and 116 (37.7%) Female, and the median age was 57 (50-66). The proportion of CD8+ T cells and natural killer cell in tumor was statistically different. The proportion of CD8+ T cells in NSCLC, Colorectal cancer, Hepatobiliary cancer and others was 2.16%, 1%, 1.77% and 2.63%, p < 0.01; the proportion of natural killer cell was 16.44 %, 4.91%, 5.58% and 3.29%, p < 0.01. Conclusions: Different tumor types have different immune microenvironments. These results may provide valuable clues for future ICI trail design.

Download Full-text